Craft

Biogen

Stock Price

$183.5

2024-10-29

Market Capitalization

$26.7 B

2024-10-29

Revenue

$9.7 B

FY, 2024

Biogen Summary

Company Summary

Overview
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. It offers medicines and therapies in the areas of lupus, multiple sclerosis, postpartum depression, spinal muscular atrophy, etc.
Type
Public
Status
Active
Founded
1978
HQ
Cambridge, MA, US | view all locations
Website
https://www.biogen.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Stelios Papadopoulos

    Stelios Papadopoulos, Chairman of the Board

    • Susan Alexander

      Susan Alexander, Chief Legal Officer and Secretary

    • Martin Dubuc

      Martin Dubuc, Head of Biogen Digital Health

      • Michael McDonnell

        Michael McDonnell, Chief Financial Officer

        Operating MetricsView all

        Floor Space Owned (RTP, North Carolina), sq. ft.

        1M

        FY, 2021

        Warehouse Facilities Leased (Durham, North Carolina), sq. ft.

        65K

        FY, 2021

        Products (Multiple Sclerosis and Neuroimmunology)

        6

        FY, 2021

        LocationsView all

        48 locations detected

        • Cambridge, MA HQ

          United States

          225 Binney St

        • Morrisville, NC

          United States

          5000 Davis Dr

        • South San Francisco, CA

          United States

          6000 Shoreline Ct #304

        • Washington, DC

          United States

          701 Pennsylvania Avenue NW #715

        • Vicente López, Buenos Aires

          Argentina

          7th Floor, Av. del Libertador 350

        • Macquarie Park, NSW

          Australia

          2 Banfield Rd

        and 42 others

        Biogen Financials

        Summary Financials

        Revenue (Q1, 2025)
        $2.4B
        Gross profit (Q1, 2025)
        $1.8B
        Net income (Q1, 2025)
        $240.5M
        Cash (Q1, 2025)
        $2.6B
        Enterprise value
        $30.4B

        Footer menu